6-(甲氧基羰基)吡啶-3-硼酸 | 1072945-86-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(甲氧基羰基)吡啶-3-硼酸
• 中文别名: 6-(甲氧羰基)吡啶-3-硼酸；2-(甲基羧基)吡啶-5-硼酸
• 英文名称: (6-(methoxycarbonyl)pyridin-3-yl)boronic acid
• 英文别名: 2-(methylcarboxy)pyridine-5-boronic acid；6-(methoxycarbonyl)pyridine-3-ylboronic acid；(6-methoxycarbonyl-3-pyridyl)boronic acid；(6-methoxycarbonylpyridin-3-yl)boronic acid
• CAS: 1072945-86-8
• 化学式: C₇H₈BNO₄
• mdl: MFCD09800559
• 分子量: 180.956
• InChiKey: OJRWQJNSMWIFMD-UHFFFAOYSA-N

物化性质

• 沸点：
  397.7±52.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.27
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  79.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R37/38,R41
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-(Methoxycarbonyl)pyridine-3-boronic acid
Synonyms: 6-(Methoxycarbonyl)pyridin-3-ylboronic acid, methyl 5-boronopyridine-2-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-(Methoxycarbonyl)pyridine-3-boronic acid
CAS number: 1072945-86-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8BNO4
Molecular weight: 181.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-(甲氧基羰基)吡啶-3-硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 碳酸氢钠 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 5-(7-(4-hydroxycyclohexyl)-2-(((S)-1-methoxypropan-2-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-isopropylpicolinamide
  参考文献：
  名称：

  [EN] PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES
  [FR] COMPOSÉS DE PYRROLOTRIAZINE ET PROCÉDÉS D'INHIBITION DE KINASES TAM

  摘要：

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗癌症的方法。其中，R1为吡啶-3-基、吡啶-4-基、吡唑-4-基、环己基或8-氮杂双环[3.2.1]辛-2-烯-3-基，其中R1可选择性地与最多四个独立选择的取代基取代；R2为环己基，其与羟基取代，并可选择性地与一个或两个额外的独立选择的来自C1-C4烷基和氟的取代基取代，或者为4,5,6,7-四氢-1H-吲哚基，可选择性地与一个至三个独立选择的来自C1-C4烷基和氟的取代基取代；R3为-C3-C8烷基、-(C2-C6烷基)-O-(C1-C6烷基)、C3-C6环烷基或-(C2-C6烷基)-C3-C6环烷基，其中R3可选择性地与1-5个独立选择的氘、卤素和-OH取代。

  公开号：

  WO2019074962A1

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] IMIDAZOLE-DERIVED MODULATORS OF THE GLUCOCORTICOID RECEPTOR<br/>[FR] MODULATEURS DU RÉCEPTEUR GLUCOCORTICOÏDE DÉRIVÉS DE L'IMIDAZOLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015027015A1

  公开（公告）日：2015-02-26

  Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-kB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.

  提供了一种新型的非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-kB活性调节相关的疾病或紊乱，包括代谢性、炎症性和免疫性疾病或紊乱，其结构如下式（I）：其对映体、二对映体或互变异构体，或其前药酯，或其药用可接受盐，其中变量如规范中所定义。
• A DNA‐Encoded Chemical Library Incorporating Elements of Natural Macrocycles
  作者：Cedric J. Stress、Basilius Sauter、Lukas A. Schneider、Timothy Sharpe、Dennis Gillingham

  DOI：10.1002/anie.201902513

  日期：2019.7.8

  Here we show a seven‐step chemical synthesis of a DNA‐encoded macrocycle library (DEML) on DNA. Inspired by polyketide and mixed peptide‐polyketide natural products, the library was designed to incorporate rich backbone diversity. Achieving this diversity, however, comes at the cost of the custom synthesis of bifunctional building block libraries. This study outlines the importance of careful retrosynthetic

  在这里，我们展示了在DNA上进行DNA编码的大环文库（DEML）的七步化学合成。受聚酮化合物和肽-聚酮化合物混合天然产物的启发，该文库旨在整合丰富的骨架多样性。但是，要实现这种多样性，就要以双功能构件块库的定制合成为代价。这项研究概述了在DNA编码文库中仔细进行逆向合成设计的重要性，同时揭示了需要新的DNA合成方法的领域。
• PIPERIDINE DERIVATIVES FOR GPR119 AGONIST
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US20150166480A1

  公开（公告）日：2015-06-18

  The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

  本发明涉及新型的哌啶衍生物、它们的立体异构体或药用可接受的盐；制备该化合物的方法；以及包含该化合物的药物组合物。根据本发明，具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢紊乱，包括糖尿病（尤其是II型）及相关疾病。
• Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7<i>H</i>-thieno[3,2-<i>b</i>]pyran-7-ones Designed as Next Generation PI3K Inhibitors
  作者：Guillermo A. Morales、Joseph R. Garlich、Jingdong Su、Xiaodong Peng、Jessica Newblom、Kevin Weber、Donald L. Durden

  DOI：10.1021/jm301522m

  日期：2013.3.14

  has made PI3K a consensus target to inhibit as illustrated by more than 15 inhibitors now in clinical trials. Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials. This inhibitor has properties that impart more in vivo activity than should be warranted

  磷脂酰肌醇-3-激酶（PI3K）通路在多种肿瘤中的失调使PI3K成为抑制的共识靶标，目前临床试验中已使用15种以上的抑制剂进行了说明。我们先前的工作是建立在早期的首创的多激酶抑制剂LY294002的基础上的，导致了唯一的PI3K血管靶向PI3K抑制剂前药SF1126，该药物现已完成I期临床试验。该抑制剂具有比其酶促效力应赋予的更多的体内活性，该酶促效力通常远低于其他临床阶段的PI3K抑制剂。我们着手探索保留了这些特性并同时展现出对PI3K更高效力的支架。这项工作导致发现了5-morpholino-7 H -thieno [3,2- b] pyran-7-one系统作为潜在的PI3K抑制剂新化合物类别的基础，对PI3K具有增强的效力。这些化合物的合成和基于癌症干细胞的活性在本文中报道。